UAV Corp and Genetic Networks
Announce Strategic Collaboration to Combat Biohazards with
Cutting-Edge Technology
Genetic Networks Signs MOU with
UMAV
Wewahitchka, FL -- April 8, 2025
-- InvestorsHub NewsWire -- UAV Corp (OTC:
UMAV), a leader in unmanned aerial vehicle (UAV)
technology, and Genetic Networks, a wholly owned subsidiary of
Fifty 1 Labs, Inc. (OTC: FITY) and a pioneer in genetic
perturbation and drug discovery, are excited to announce the
signing of a Memorandum of Understanding (MOU) on April 07, 2025.
This strategic partnership aims to develop innovative solutions for
detecting and countering biohazards, contaminants, and related
threats, leveraging UAV Corp's advanced aerial systems and Genetic
Networks' proprietary GeneScape™ platform to enhance public safety,
health, and security globally.
The collaboration integrates state-of-the-art "sniffer"
technologies into UAV Corp's airships and drones, enabling
real-time detection of nuclear, chemical, and biological hazards.
Genetic Networks, under the umbrella of Fifty 1 Labs, Inc. (OTC:
FITY), contributes its expertise in biohazard identification and
drug development—including a patented compound with potential
broad-spectrum efficacy against infections—to create
countermeasures deployable via UAV Corp's aerial platforms. Initial
testing will occur on UAV Corp's airship, currently under
completion at its Wewahitchka facility, advancing aerial threat
response capabilities.
Both companies are actively engaged in Department of Defense (DoD)
contracts, positioning them to assist each other in meeting
stringent government requirements. UAV Corp's UAV expertise
complements Genetic Networks' advancements in genetic science,
offering mutual support for DoD initiatives. On April 1, 2025, FITY
announced a groundbreaking yeast experiment launched on SpaceX's
Fram2 mission, engineered by Dr. Corey Nislow to study resistance
to microgravity and cosmic radiation—data that could inform this
collaboration's countermeasure development. Genetic Networks
will facilitate introductions between their relationships and
UMAV's management team to potentially unlock new opportunities for
contracts and collaborations in the defense and space sectors.
"This partnership merges cutting-edge aerial technology with
genetic innovation to tackle critical global challenges," said
Michael Lawson, CEO of UAV Corp. "By equipping our UAV platforms
with advanced detection systems and collaborating with Genetic
Networks, we're set to deliver rapid, impactful solutions to
biohazard threats worldwide while strengthening our DoD efforts and
exploring new avenues."
Gennaro D'Urso, Founder, CEO, and Chairman of Genetic Networks,
added, "Teaming up with UAV Corp amplifies the reach of our
GeneScape™ platform and drug development efforts, as demonstrated
by our recent SpaceX Fram2 mission experiment under Fifty 1 Labs,
Inc. (OTC: FITY). Together, we're poised to detect dangers and
deploy life-saving countermeasures efficiently, utilizing our
supplier network of approximately 4,000 generic formulations and
supporting our shared DoD objectives."
Key initiatives outlined in the
MOU include:
•
Detection Systems: Integrating sniffer technologies into UAV
platforms to identify contaminants and biohazards.
•
Countermeasures: Developing and distributing compounds to
neutralize threats, including radiation and toxic substances, via
aerial delivery.
•
Distribution Partnership: Exploring Genetic Networks' potential
role as an exclusive agent for countermeasure distribution,
supported by UAV Corp's aerial capabilities.
•
Joint R&D: Combining whole-genome analysis with UAV expertise
to refine detection and response strategies.
The two-year collaboration, effective from the signing date,
reflects both companies' dedication to innovation and societal
benefit. While the MOU serves as a non-binding framework, the
parties plan to formalize specific projects and funding through
subsequent agreements, with testing timelines to be detailed
soon.
"We're thrilled to launch this partnership," Lawson and D'Urso said
jointly. "It strengthens our capabilities, aligns our DoD efforts,
and positions us to make a tangible impact on global health and
security."
About UAV Corp
UAV Corp (OTC: UMAV) is a global leader in unmanned aerial vehicle
technology, delivering advanced solutions for security,
surveillance, and aerial systems across government, defense, and
commercial sectors. Headquartered in Wewahitchka, Florida, UAV Corp
is committed to advancing aerial innovation.
Michael Lawson, CEO
Email: mlawson@uavcorp.net
Address: 115 County Road 381, Wewahitchka, FL 32465
Phone: 877-425-1066
Website: www.uavcorp.net
About Genetic
Networks
Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc.
(OTC: FITY), accelerates drug discovery and compound development
through its proprietary GeneScape™ platform. The company is
dedicated to advancing health solutions through genetic science and
strategic partnerships
Investor
Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
